drugset / Trial / NCT02978599
Clinical Trial of AVL-3288 in Schizophrenia Patients
Phase 1
Completed
24 enrolled
New York State Psychiatric Institute
National Institute of Mental Health (NIMH) · collab
RandomizedCrossoverTriple-blindTreatment
Summary
Single-center, outpatient, randomized, double-blind, placebo-controlled, 3-treatment-phase, cross-over study to evaluate the safety, tolerability and efficacy of two oral doses of AVL-3288 each compared to placebo, in patients with schizophrenia.
Timeline
- Start
- 2016-11
- Primary completion
- 2018-10-26
- Completion
- 2018-11-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AVL-3288 | Small molecule | 10 mg | Oral |
| Subject | AVL-3288 | Small molecule | 30 mg | Oral |